CARB-X is a biopharmaceutical business enterprise that specializes in biotechnology, antibiotics, vaccines, fast diagnostics.
Accelerate a diverse portfolio of at least 20 high-quality antibacterial products towards clinical development leveraging $250 million in BARDA funds with matching funds from the Wellcome Trust and the AMR Centre.
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Feb 1, 2021
Avails Medical
|
Grant | $2.50M | Health Care | Yes |
Aug 11, 2020
Evotec
|
Grant | $2.91M | Biopharma | Yes |
Oct 1, 2019
Trellis Bioscience
|
Grant | $3.20M | Biotechnology | Yes |